一分钟看懂
这是一项关于尿路上皮癌的II 期研究，登记的药物或干预包括RAG-01；Chemotherapy agent，当前状态为尚未开始招募。登记地点显示中国上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
RAG-01；Chemotherapy agent · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Fudan University Shanghai Cancer Center · 上海
公开的入选条件
- 1. Voluntarily agrees to participate in this study and provides written informed consent prior to the initiation of any study-specific procedures.
- 2. Is aged ≥18 years at the time of signing the informed consent form (ICF).
- 3. Has histologically confirmed tumor tissue obtained within 12 weeks prior to the first study treatment, with urothelial carcinoma as the predominant histologic subtype (≥90%), and is classified according to the American Urological Association (AUA) guideline
- Cohort A: high-risk non-muscle-invasive bladder cancer (NMIBC).
- Cohort B: intermediate-risk NMIBC.
- 4. Regardless of prior bacillus Calmette-Guérin (BCG) treatment, is confirmed before enrollment to be BCG-intolerant, ineligible for BCG, unwilling to receive BCG, or unable to access BCG treatment for any reason.
- 5. Has no resectable lesion, as confirmed by cystoscopy and/or transurethral resection of bladder tumor (TURBT), within 12 weeks prior to the first administration of study treatment.
- 6. Is willing to provide pathological tissue specimens.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07777848；登记信息更新于 2026-09-15。